Welcome to our dedicated page for Haleon SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Haleon plc (HLN) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on both the London Stock Exchange and the New York Stock Exchange. Haleon files annual reports on Form 20-F and submits current reports on Form 6-K under the Securities Exchange Act of 1934. These filings cover topics such as trading statements, total voting rights and capital, board and committee changes, and transactions by persons discharging managerial responsibilities (PDMRs).
Recent 6-K filings include announcements on Haleon’s Q3 trading statement, regular updates on total voting rights and capital, and detailed notifications of share transactions under the company’s share reward plans by senior managers. Other filings describe governance developments, such as the appointment of a new Chair, changes to the Senior Independent Director role and committee memberships, and the evolution of Haleon’s operating model, including the creation of six Operating Units and new executive roles like Chief Growth Officer and Chief Transformation Officer.
Many filings contain an "About Haleon" section that reiterates the company’s profile as a global leader in consumer health with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other, along with examples of long-standing brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren.
On this page, investors can review Haleon’s SEC submissions as they are made available from EDGAR, while AI-powered tools on the platform can help summarise key points, highlight changes over time and surface information on areas such as capital structure, insider share dealings disclosed as PDMR transactions, and updates to the company’s governance and operating model.
Haleon plc announced the purchase and cancellation of 1,399,293 ordinary shares of each under the second tranche of its share buyback programme announced 31 July 2025. Trades executed on 14 August 2025 on the London Stock Exchange/CBOE UK totalled 1,399,293 shares at an average price of 58.7136. After settlement, registered share capital is 8,974,906,495 ordinary shares, of which 3,880,205 are treasury shares, leaving 8,971,026,290 ordinary shares with voting rights for disclosure threshold purposes. A full trade breakdown is available via the provided RNS link and the company's investor website.
Haleon has completed a tranche of its announced share buyback, purchasing 830,000 ordinary shares for cancellation on 13 August 2025 at a volume-weighted average price of 356.7308p. The purchases on the London Stock Exchange ranged between 354.7000p and 358.6000p.
After settlement the company reports a registered share capital of 8,976,305,788 ordinary shares, of which 3,880,205 are held in treasury, leaving 8,972,425,583 voting shares. A full trade breakdown is available from the company’s announcement link and on its investor website.
Haleon plc announced the purchase and cancellation of 1,400,000 ordinary shares of \u00A3 .01 each under the second tranche of its buyback programme. The purchases occurred on 12 August 2025 on the London Stock Exchange with a highest price of 356.1000p, lowest of 353.2000p and a volume weighted average price of 354.8037p.
After settlement the company reports registered share capital of 8,977,135,788 ordinary shares, of which 3,880,205 are held as treasury shares, leaving 8,973,255,583 ordinary shares with voting rights. The announcement includes a breakdown of individual trades under the Market Abuse Regulation and provides links for shareholders to verify holdings for FCA notification thresholds.
Haleon plc disclosed director/PDMR share transactions showing that two senior officers participated in the company's Share Reward Plan. Adrian Morris (General Counsel) and Tamara Rogers (Chief Marketing Officer) each acquired 36 Partnership Shares at £3.563199 per share and were awarded 36 Matching Shares at nil cost, for an aggregated 72 shares each. The transactions occurred on 11 August 2025 on the London Stock Exchange and were announced by the company, reflecting routine compensation-related share acquisitions under its Share Reward Plan.
Haleon plc purchased 1,200,000 ordinary shares of £0.01 each for cancellation under the second tranche of its share buyback programme announced 31 July 2025. Purchases took place on 11 August 2025 on the London Stock Exchange with a highest price of 357.0000p, lowest price of 352.2000p and a volume-weighted average price of 354.2107p. After settlement, registered share capital is 8,978,535,788 ordinary shares, with 3,880,205 held as treasury, leaving 8,974,655,583 ordinary shares with voting rights. A full trade breakdown is published via the provided RNS link and on the company's investor website; the announcement states it does not constitute an offer.
Haleon plc purchased 856,760 ordinary shares of £0.01 each for cancellation under the second tranche of its share buyback programme announced 31 July 2025. The purchases were executed on 08 August 2025 on the London Stock Exchange at prices between 353.5000p and 356.1000p, with a volume-weighted average price of 354.6173p.
Following settlement the company's registered share capital is 8,979,735,788 ordinary shares, of which 3,880,205 are held as treasury shares, leaving 8,975,855,583 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided RNS link and on Haleon's investor website.
Haleon plc (LSE/NYSE: HLN) filed a Form 6-K to report activity under the second tranche of its share-buyback programme announced on 31 July 2025. On 7 August 2025 the company purchased 1,330,960 ordinary shares (nominal £0.01) for cancellation on the London Stock Exchange at prices between 346.5p – 354.4p, delivering a volume-weighted average price of 351.6198p.
Post-settlement, Haleon’s registered share capital stands at 8,980,592,548 ordinary shares, of which 3,880,205 are held in treasury, leaving 8,976,712,343 voting shares outstanding. A detailed trade log is available via the RNS link and on the company’s investor website. No other material financial information or guidance is provided in this filing.
Haleon plc’s 7 Aug 2025 Form 6-K encloses a UK TR-1 notice showing Wellington Management Group LLP has fallen below the 5 % disclosure threshold.
- Date threshold crossed: 6 Aug 2025
- Current holding: 4.96 % of voting rights (445,697,628 votes)
- Prior holding: 5.29 %
- Break-down: 4.66 % ordinary shares (418.6 m votes), 0.29 % depositary receipts (26.4 m votes), 0.01 % cash-settled equity swaps (0.64 m votes)
- Change: roughly 0.33 ppt (≈28 m votes) disposed
The disclosure is mandatory under FCA DTR 5 and does not include earnings or operational updates. Investors may view the reduced stake as a marginal decline in long-only institutional ownership; however, no immediate strategic implications were provided.
Haleon plc has filed a Form 6-K outlining the latest activity under the second tranche of its share-buyback programme announced on 31 July 2025.
On 6 Aug 2025 the company repurchased 1,517,728 ordinary shares on the London Stock Exchange at a volume-weighted average price of 347.5568 p (high 350.3000 p, low 346.3000 p). No shares were bought on Cboe BXE or CXE. All acquired shares will be cancelled.
Post-transaction, Haleon’s issued share capital totals 8,981,923,508 shares of £0.01 each, with 3,880,205 held in treasury, leaving 8,978,043,303 voting shares outstanding. The purchase equates to roughly 0.017 % of shares in issue and does not materially alter the company’s capital structure.
No earnings figures, guidance, or other material financial disclosures accompany this filing. The update is chiefly administrative, confirming incremental progress toward the ongoing buyback plan.
FAQ
What is the current stock price of Haleon (HLN)?
What is the market cap of Haleon (HLN)?
